An association between BRAF mutation positivity and aggressive tumor phenotype (extrathyroidal extension, lymph node metastasis) hes been reported, with a higher risk of recurrent and persistent disease [5,6], especially when TERT promoter mutation coexists [7,8]. Here, BRAF is linked to metastatic malignant neoplasm in the lymph nodes.